Financials PepGen Inc.

Equities

PEPG

US7133171055

Biotechnology & Medical Research

Market Closed - Nasdaq 21:00:00 17/05/2024 BST 5-day change 1st Jan Change
13.16 USD -3.59% Intraday chart for PepGen Inc. -6.07% +93.53%

Valuation

Fiscal Period: December 2022 2023 2024 2025 2026
Capitalization 1 316 161.9 426.6 - -
Enterprise Value (EV) 1 134.2 81.16 314.9 264.5 426.6
P/E ratio -3.02 x -2.06 x -4.64 x -4.67 x -8.15 x
Yield - - - - -
Capitalization / Revenue - - - 85.4 x 11.4 x
EV / Revenue - - - 52.9 x 11.4 x
EV / EBITDA -1.98 x -0.97 x -2.95 x -2.17 x -
EV / FCF -2.13 x -1.13 x -3.31 x -2.58 x -4.68 x
FCF Yield -47% -88.2% -30.2% -38.7% -21.4%
Price to Book - - - - -
Nbr of stocks (in thousands) 23,632 23,814 32,417 - -
Reference price 2 13.37 6.800 13.16 13.16 13.16
Announcement Date 23/03/23 06/03/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2021 2022 2023 2024 2025 2026
Net sales 1 - - - - 4.995 37.46
EBITDA 1 - -67.81 -83.58 -106.9 -121.8 -
EBIT 1 - -68.3 -84.77 -75.11 -98.43 -55.41
Operating Margin - - - - -1,970.62% -147.92%
Earnings before Tax (EBT) 1 - -65.4 -78.55 -102.2 -118.9 -106.5
Net income 1 -27.28 -69.1 -78.63 -82.59 -103.3 -64.73
Net margin - - - - -2,067.65% -172.8%
EPS 2 -29.74 -4.420 -3.300 -2.835 -2.818 -1.615
Free Cash Flow 1 - -63.02 -71.6 -95.22 -102.3 -91.24
FCF margin - - - - -2,048.51% -243.57%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share 2 - - - - - -
Announcement Date 15/04/22 23/03/23 06/03/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 - - - - - - - - - - - -
EBITDA - - - - -17.88 - - -20.46 - - - -
EBIT 1 -13.89 -17.64 -19.55 -17.21 -18.03 -21.14 -24.78 -20.81 -19.8 -22.4 -21.9 -89.31
Operating Margin - - - - - - - - - - - -
Earnings before Tax (EBT) 1 -13.83 -17.32 -18.61 -15.65 -16.32 -19.52 -23.29 -19.42 -18.02 -24.68 -26.42 -28.1
Net income 1 -18.25 -17.32 -18.61 -14.94 -16.32 -19.52 -23.29 -19.5 -18.02 -20.5 -21.12 -21.32
Net margin - - - - - - - - - - - -
EPS 2 -18.94 -1.230 -0.7900 -0.2400 -0.6900 -0.8200 -0.9800 -0.8100 -0.6300 -0.7100 -0.7250 -0.7150
Dividend per Share - - - - - - - - - - - -
Announcement Date 16/06/22 12/08/22 10/11/22 23/03/23 11/05/23 08/08/23 08/11/23 06/03/24 14/05/24 - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - -
Net Cash position 1 - 182 80.8 112 162 -
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 - -63 -71.6 -95.2 -102 -91.2
ROE (net income / shareholders' equity) - -93.7% -54.6% -115% - -
ROA (Net income/ Total Assets) - - - - - -
Assets 1 - - - - - -
Book Value Per Share - - - - - -
Cash Flow per Share 2 - -3.790 -2.900 -3.180 -2.970 -
Capex 1 - 3.76 2.6 5.3 4.99 8.27
Capex / Sales - - - - 99.99% 22.07%
Announcement Date 15/04/22 23/03/23 06/03/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
13.16 USD
Average target price
21.6 USD
Spread / Average Target
+64.13%
Consensus
  1. Stock Market
  2. Equities
  3. PEPG Stock
  4. Financials PepGen Inc.